Please login to the form below

Not currently logged in
Email:
Password:

Cardiovascular outcomes

This page shows the latest Cardiovascular outcomes news and features for those working in and with pharma, biotech and healthcare.

Bayer’s finerenone scores FDA priority review for chronic kidney disease

Bayer’s finerenone scores FDA priority review for chronic kidney disease

Overactivation of the mineralocorticoid receptor is believed to play a key role in kidney and cardiovascular damage, through inflammatory and fibrotic processes. ... The key secondary endpoint, which measures cardiovascular outcomes, found that the

Latest news

  • Novo Nordisk launches late-stage study in Alzheimer’s disease Novo Nordisk launches late-stage study in Alzheimer’s disease

    Also, in post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk, which included 15, 820 patients with type 2 diabetes and a median follow-up

  • Novartis scores CHMP backing for cholesterol drug Leqvio Novartis scores CHMP backing for cholesterol drug Leqvio

    in adults with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent and heterozygous familial hypercholesterolemia (HeFH). ... Another trial, dubbed ORION-4, is currently underway to determine if the reduction in LDL-C is coupled with an

  • Esperion gets FDA thumbs up for cholesterol drug Nexletol Esperion gets FDA thumbs up for cholesterol drug Nexletol

    outcomes study – not due to generate results until 2022 – before approval might be possible. ... Nexletol won’t be able to make a similar claim unless its cardiovascular outcomes trial comes out positive in 2022.

  • Novartis plans inclisiran trial in the UK Novartis plans inclisiran trial in the UK

    Swiss pharma also officially opens new London headquarters. Novartis announced yesterday that the UK will become the global centre a new clinical trial investigating inclisiran in improving cardiovascular outcomes. ... As a company working to improve and

  • Novo Nordisk gets MACE prevention claim for Ozempic in US Novo Nordisk gets MACE prevention claim for Ozempic in US

    Novo Nordisk is hoping that collective data from the PIONEER trials programme could help it get a cardiovascular outcomes claim for Rybelsus later this year. ... Otherwise, it is also conducting a dedicated cardiovascular outcomes trial for Rybelsus –

More from news
Approximately 1 fully matching, plus 132 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Prof Sir Mike Richards joins Incisive Health as senior counsel Prof Sir Mike Richards joins Incisive Health as senior counsel

    In July 2012 he was appointed as Director for Reducing Premature Mortality on the NHS Commissioning Board (now NHS England), where he led the development of a cardiovascular outcomes strategy. ... These are vital attributes if the NHS is to navigate the

  • Teva's Mark Salyer joins Amarin Teva's Mark Salyer joins Amarin

    Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • World Heart Day 2020: It's time to make our clinical trials more inclusive World Heart Day 2020: It's time to make our clinical trials more inclusive

    Disparities in cardiovascular health outcomes between different ethnic groups. Despite the progress that’s been made in treating heart disease, there is still a huge difference in mortality between white people ... Health outcomes are also related to

  • A new vision for tackling key illnesses

    It also looks at other areas, such as cardiovascular and respiratory conditions, and explains how the NHS plans to change its approach in order to drive improvements in patient care and ... outcomes.  . Cardiovascular disease (CVD)  . Cardiovascular

  • Conference research case study

    Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and ... Communication strategies and marketing messages were

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....